Ellex Medical Lasers Ltd (ASX:ELX) will present a positive 12-month case series data for the company’s proprietary ABiC minimally invasive glaucoma surgery (MIGS) procedure at the American Society of Cataract and Refractive Surgery meeting in New Orleans, U.S.A.
Ellex manufactures lasers and other medical devices for the diagnosis and treatment of eye disease.
The results from the case series study show that ABiC can effectively reduce intraocular pressure (IOP or fluid pressure inside the eye) and medication dependence in glaucoma patients with minimal complications.
The case series study, which was undertaken in the U.S., included 228 eyes with mild-to-moderate glaucoma who underwent ABiC either alone or in combination with cataract surgery.
Encouragingly, in 98 patients who underwent ABiC as a standalone procedure, there was an average decrease of 36.74% in IOP and 66.66% in medications.
Data for the entire patient cohort showed a total average decrease of 30% in IOP and a 50% reduction in medications, 12 months after the ABiC surgery.
The company had developed ABiC to address the shortcomings of conventional glaucoma treatment options, which includes chronic use of daily multi-dose topical glaucoma medications.
Since launching ABiC into the fast-growing MIGS market, Ellex has achieved sales growth in the U.S of 25% during the 9 months to 31 March 2016, compared with the prior corresponding period.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.